AxoSim empowers advancements in human neuroscience and accelerates the drug development process through our drug discovery platforms, NerveSim® and BrainSim®
Learn More
Our technology enables researchers to predict human outcomes in the lab. We deliver accurate preclinical testing to help develop safer, more effective drugs.
Almost 90% of drugs that look promising in animal models fail when tested in humans, driving up the average cost and time of new drug development to $2.6 billion and 10 years or more. We deliver predictive human data in just weeks and at a fraction of the cost of in vivo studies.
Achieve the predictive readouts critical to your R&D success. We deliver clinically-relevant functional and structural metrics to improve success rates.
AxoSim's NerveSim® platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
BrainSim® is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery.
Our CEO Lowry Curley, PhD, had the honor of being quoted in Genetic Engineering and Biotechnology New’s July cover story. The article, written […]
Read MoreCommentary by AxoSim Scientist Wesley Anderson, PhD In vitro neuronal models provide scientists with simple and quick methods to study the nervous […]
Read MoreAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects approximately 13 per 100,000 individuals. Although many potential mechanisms for ALS […]
Read MoreSpring 2021 In addition to our proprietary platforms NerveSim® and BrainSim®, we are excited to announce the expansion of our SimLab Services: advanced neuronal […]
Read More
